Clinical Trial Update: A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating E3810 for non-erosive gastroesophageal reflux disease using pre- and post-treatment pH monitoring was completed, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-erosive Gastroesophageal Reflux Disease

Drugs mentioned

• E3810

Snippet

Sponsor: Eisai Inc. | Conditions: Non-erosive Gastroesophageal Reflux Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-10-05